专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP2068895A4 SELECTIVE CHEMOKINE MODULATION 有权
标题翻译：选择性调节
公开(公告)号：EP2068895A4
公开(公告)日：2009-12-23
申请号：EP07808800
申请日：2007-09-11
申请人： PROPHY MED AB
发明人： BRUCE LARS , LYNGSTADAAS STAALE PETTER
IPC分类号： A61K33/24 , A61K33/08 , A61K33/32 , A61P29/00 , A61P37/02 , A61P37/04 , A61P37/06 , B01D15/10 , B01D15/20 , B01D15/22
CPC分类号： A61M1/38 , A61K9/14 , A61K33/24 , A61M1/3679 , B01J20/02 , B01J20/06
摘要： The present invention teaches the use of a metal or an oxide of a metal having a capability of reducing the amount of the chemokine IP-IO in a sample and/or reducing the production of IP-IO in cells. The metal is a metal of group 4 or 5 in the periodic table of the elements and preferably titanium. These metals and metal oxides can selectively bind IP-IO to its surface to thereby scavenge IP-IO from the surrounding medium. In addition, a metal-cell contact induces a reduction in the production of IP-IO from IP-IO producing cells. The metals and metal oxides of the present invention can therefore be used for treating and/or preventing medical conditions characterized by adverse IP-IO expression, such as inflammatory reactions.
摘要翻译：治疗或预防以10kDa干扰素-γ可诱导蛋白（IP-10）的不良表达和/或释放为特征的疾病的方法包括将由金属或金属氧化物制成的颗粒或颗粒施用于患有疾病。在患有特征在于IP-10的不良表达和/或释放的疾病的受试者中减少IP-10的方法包括向受试者施用由金属或金属氧化物制成的颗粒或颗粒。金属是元素周期表第4或5族的金属，选自钛，锆，铪，铌和钽。

2. 发明公开

EP1476186A1 USE OF AN INHIBITOR OR ANTAGONIST AGAINST TISSUE FACTOR 审中-公开
标题翻译：使用组织因子抑制剂或拮抗药
公开(公告)号：EP1476186A1
公开(公告)日：2004-11-17
申请号：EP03705622.3
申请日：2003-02-21
申请人： Prophy Med AB
发明人： KORSGREN, Olle , NILSSON, Bo
IPC分类号： A61K39/395 , A61K38/28 , A61K48/00 , A61P3/10 , A61P9/00 , A61P7/02
CPC分类号： C07K16/36 , A61K38/1709 , A61K2039/505
摘要： The present invention relates to use of an inhibitor or antagonist against tissue factor, TF, in the production of a drug for treatment or prevention of diabetes or diabetes related diseases. The inhibitor or antagonist is mainly intended for treatment of diabetic patients suffering from type I or type II diabetes, respectively, as well as the metabolic syndrome preceding type II diabetes. The inhibitor or antagonist is an agent which completely or partially inhibits TF productions, such as an anti-TF antibody or an antisense construct acting on the TF gene.

3. 发明授权

EP2068895B1 SELECTIVE CHEMOKINE MODULATION 有权
标题翻译：选择性趋化因子调制
公开(公告)号：EP2068895B1
公开(公告)日：2012-12-12
申请号：EP07808800.2
申请日：2007-09-11
申请人： Prophy Med AB
发明人： BRUCE, Lars , LYNGSTADAAS, Staale Petter
IPC分类号： A61K33/24 , A61P29/00 , A61P37/02 , A61P37/04 , A61P37/06 , A61K33/08 , A61K33/32 , B01D15/10 , B01D15/20 , B01D15/22
CPC分类号： A61M1/38 , A61K9/14 , A61K33/24 , A61M1/3679 , B01J20/02 , B01J20/06 , Y02A50/387
摘要： The present invention teaches the use of a metal or an oxide of a metal having a capability of reducing the amount of the chemokine IP-IO in a sample and/or reducing the production of IP-IO in cells. The metal is a metal of group 4 or 5 in the periodic table of the elements and preferably titanium. These metals and metal oxides can selectively bind IP-IO to its surface to thereby scavenge IP-IO from the surrounding medium. In addition, a metal-cell contact induces a reduction in the production of IP-IO from IP-IO producing cells. The metals and metal oxides of the present invention can therefore be used for treating and/or preventing medical conditions characterized by adverse IP-IO expression, such as inflammatory reactions.

4. 发明公开

EP2068895A1 SELECTIVE CHEMOKINE MODULATION 有权
标题翻译：选择性趋化因子调节
公开(公告)号：EP2068895A1
公开(公告)日：2009-06-17
申请号：EP07808800.2
申请日：2007-09-11
申请人： Prophy Med AB
发明人： BRUCE, Lars , LYNGSTADAAS, Staale Petter
IPC分类号： A61K33/24 , A61P29/00 , A61P37/02 , A61P37/04 , A61P37/06
CPC分类号： A61M1/38 , A61K9/14 , A61K33/24 , A61M1/3679 , B01J20/02 , B01J20/06 , Y02A50/387
摘要： The present invention teaches the use of a metal or an oxide of a metal having a capability of reducing the amount of the chemokine IP-IO in a sample and/or reducing the production of IP-IO in cells. The metal is a metal of group 4 or 5 in the periodic table of the elements and preferably titanium. These metals and metal oxides can selectively bind IP-IO to its surface to thereby scavenge IP-IO from the surrounding medium. In addition, a metal-cell contact induces a reduction in the production of IP-IO from IP-IO producing cells. The metals and metal oxides of the present invention can therefore be used for treating and/or preventing medical conditions characterized by adverse IP-IO expression, such as inflammatory reactions.
摘要翻译：本发明教导了具有减少样品中趋化因子IP-10的量和/或减少细胞中IP-10产生的能力的金属或金属氧化物的用途。金属是元素周期表中第4族或第5族的金属，优选钛。这些金属和金属氧化物可以选择性地将IP-10结合到其表面上，从而从周围介质中清除IP-10。另外，金属电池接触引起IP-IO产生细胞产生IP-10的减少。因此，本发明的金属和金属氧化物可以用于治疗和/或预防以不利的IP-10表达为特征的医学病症，例如炎性反应。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式